近日,索爾福德大學(xué)的研究人員在《Nature》上發(fā)表了題為“Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase”的論文。研究人員通過分離具有侵襲性的高ATP水平癌細(xì)胞亞群,證實(shí)了,F(xiàn)DA批準(zhǔn)的Bedaquiline藥物通過靶向ATP合酶的γ亞基(ATP5F1C),來抑制體內(nèi)線粒體ATP的產(chǎn)生和轉(zhuǎn)移。